BRUSSELS Belgian pharmaceutical group UCB on Thursday reported a better-than-expected core profit in the first half of 2016, as it reduced operating expenses and its inflammatory disease drug Cimzia performed well.
Core profit rose 18 percent in the first half to 549 million euros ($607.5 million), above the 518 million euros expected in a Reuters poll.
16:22 Trump's first 100 days: Here's what to expect from the market21
21:45 Netflix posts its biggest-ever quarterly subscriber growth, stock surges 8%15
11:20 PE firm Warburg buys $121 million stake in Indian cinema operator PVR15
02:14 Green Bay Packers expected to cut Sam Shields21